These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22635024)

  • 1. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
    Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
    Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
    Murayama-Hosokawa S; Oda K; Nakagawa S; Ishikawa S; Yamamoto S; Shoji K; Ikeda Y; Uehara Y; Fukayama M; McCormick F; Yano T; Taketani Y; Aburatani H
    Oncogene; 2010 Apr; 29(13):1897-908. PubMed ID: 20062086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
    Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
    Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability.
    Fujii H; Matsumoto T; Yoshida M; Furugen Y; Takagaki T; Iwabuchi K; Nakata Y; Takagi Y; Moriya T; Ohtsuji N; Ohtsuji M; Hirose S; Shirai T
    Hum Pathol; 2002 Apr; 33(4):421-8. PubMed ID: 12055677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
    BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis.
    Chang KH; Albarracin C; Luthra R; Wang L; Zheng W; Malpica A; Deavers MT; Silva EG; Liu J
    Int J Gynecol Cancer; 2006; 16(1):178-82. PubMed ID: 16445630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent microsatellite instability in synchronous ovarian and endometrial adenocarcinoma and its usefulness for differential diagnosis.
    Kaneki E; Oda Y; Ohishi Y; Tamiya S; Oda S; Hirakawa T; Nakano H; Tsuneyoshi M
    Hum Pathol; 2004 Dec; 35(12):1484-93. PubMed ID: 15619207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.
    Chao A; Wu RC; Jung SM; Lee YS; Chen SJ; Lu YL; Tsai CL; Lin CY; Tang YH; Chen MY; Huang HJ; Chou HH; Huang KG; Chang TC; Wang TH; Lai CH
    Gynecol Oncol; 2016 Oct; 143(1):60-67. PubMed ID: 27498588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
    Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
    Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.
    Wu RC; Veras E; Lin J; Gerry E; Bahadirli-Talbott A; Baras A; Ayhan A; Shih IM; Wang TL
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 29162652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
    Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
    Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer.
    Ramus SJ; Elmasry K; Luo Z; Gammerman A; Lu K; Ayhan A; Singh N; McCluggage WG; Jacobs IJ; Whittaker JC; Gayther SA
    Clin Cancer Res; 2008 Sep; 14(18):5840-8. PubMed ID: 18794095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.